Start a New Search
SHOWING 216 RESULTS
Letter by associations expressing gratitude for bipartisan approval of S. 994, the Digital Accountability and Transparency Act, by the Homeland Security and Governmental Affairs Committee.
Research Administration & Regulation | Reducing Regulatory Burden | LettersLab-to-Market Inter-Agency Summit: Recommendations from the National Expert Panel
White House Conference Center May 20, 2013
Research Administration & Regulation | Technology Transfer | Intellectual Property | RecommendationWe appreciate the approach that S. 994 takes for improving the transparency of the financial information that federal grant and contract recipients report to the federal government.
Reducing Regulatory Burden | Research Administration & Regulation | LettersWe strongly believe that financial transparency of federal award funds is essential to insuring public trust.
Reducing Regulatory Burden | Research Administration & Regulation | LettersYour new bill focuses on improving data standards and reporting, as well as streamlining financial reporting.
Reducing Regulatory Burden | Research Administration & Regulation | LettersThe nation's top research universities and AAMC issued a set of shared guidelines intended to protect the public interest when universities grant licenses for the rights to their latest scientific advances to private parties.
Intellectual Property | Technology Transfer | Research Administration & Regulation | Stanford University | Press ReleasesThose concerns have centered on the imposition of redundant and costly reporting requirements. The revised bill would eliminate explicitly duplicative reporting within three years.
Research Administration & Regulation | Reducing Regulatory Burden | LettersAAU, APLU, COGR letter on proposed changes to NIH guidelines for human stem cell research and consideration of certain human-animal chimera research.
Research Administration & Regulation | National Institutes of Health | LettersRe: Retrospective Review: Identifying and Reducing Regulatory Burdens; 81 FR 4213
Research Administration & Regulation | Reducing Regulatory Burden | LettersIn the US, ketamine is currently a Schedule III drug under the Controlled Substances Act, and strict regulations and safeguards are already in place to prevent its illegal use.
Research Administration & Regulation | Reducing Regulatory Burden | Higher Education Regulation | Letters